KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Intangibles (2017 - 2025)

BeOne Medicines (ONC) has disclosed Intangibles for 7 consecutive years, with $51.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Intangibles fell 10.58% to $51.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $51.1 million, a 10.58% decrease, with the full-year FY2024 number at $51.1 million, down 10.58% from a year prior.
  • Intangibles was $51.1 million for Q4 2024 at BeOne Medicines, down from $57.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $57.1 million in Q4 2023 to a low of $5.0 million in Q4 2020.
  • A 5-year average of $38.3 million and a median of $46.8 million in 2021 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: surged 833.58% in 2021, then fell 12.99% in 2022.
  • BeOne Medicines' Intangibles stood at $5.0 million in 2020, then soared by 833.58% to $46.7 million in 2021, then decreased by 12.99% to $40.6 million in 2022, then soared by 40.68% to $57.1 million in 2023, then decreased by 10.58% to $51.1 million in 2024.
  • Per Business Quant, the three most recent readings for ONC's Intangibles are $51.1 million (Q4 2024), $57.1 million (Q4 2023), and $53.7 million (Q3 2023).